Arcoma (ARCOMA) Q2 2025 earnings summary

Executive summary

• Strong demand in Europe, while US operations were impacted by political factors and short-term uncertainty in decision-making processes.

• Order intake in the US was delayed due to political uncertainty, but underlying demand remains robust.

• A strategic new share issue of approximately SEK 11 million was completed with Eiffel Investment Group.

Financial highlights

• Q2 2025 net sales were SEK 31,378k, down from SEK 41,655k year-over-year.

• EBITDA for Q2 was SEK 1,901k (Q2 2024: SEK 5,756k), with an EBITDA margin of 6% (11%).

• Pre-tax profit for Q2 was SEK 5k (Q2 2024: SEK 3,657k); EPS was SEK 0.00 (0.23).

• Accumulated 2025 net sales were SEK 66,253k (2024: SEK 88,119k); EBITDA SEK 6,360k (12,249k); pre-tax profit SEK 2,587k (8,159k); EPS SEK 0.16 (0.50).

• Gross margin in Q2 was 39% (43%), affected by geographic and product mix.

Outlook and guidance

• Entering the next quarter with a strong project pipeline and high market presence.

• Continued focus on business quality, process improvements, and cost efficiency to maintain profitability.

• Ongoing innovation with new product functionality planned for year-end.